Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pilot Study of the Impact of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Undetectable Plasma Virus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by University of Pittsburgh.
Recruitment status was  Recruiting
National Cancer Institute (NCI)
Information provided by:
University of Pittsburgh Identifier:
First received: September 29, 2007
Last updated: October 13, 2008
Last verified: October 2008
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2009
  Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):